Identifying obstetrics patients in whom RHD genotyping can be used to assess risk of D alloimmunization Cover

.blurhash-client-img { display: none !important; }

Identifying obstetrics patients in whom RHD genotyping can be used to assess risk of D alloimmunization

Immunohematology

Volume 36 (2020): Issue 4 (December 2020)

By: T.N. Horn, J. Keller, M.A. Keller and L. Klinger

Paid access

|Jan 2020

Authors

T.N. Horn

Trina.Horn@redcross.org

National Molecular Laboratory, American Red Cross Biomedical Services, Philadelphia, Pennsylvania

J. Keller

National Molecular Laboratory, American Red Cross Biomedical Services, Philadelphia, Pennsylvania

M.A. Keller

National Molecular and Genomics Laboratories, American Red Cross Biomedical Services, Philadelphia, Pennsylvania

L. Klinger

Transfusion Service at Lankenau Institute for Medical Research, Pennsylvania

DOI: https://doi.org/10.21307/immunohematology-2020-054 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X

Journal RSS Feed

Language: English

Page range: 146 - 151

Published on: Jan 1, 2020

Published by: American National Red Cross

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

D,

blood group antigen,

alloimmunization,

RhIG prophylaxis,

hemolytic disease of fetus and newborn (HDFN)

Related subjects:

Clinical medicine,

Laboratory medicine

© 2020 T.N. Horn, J. Keller, M.A. Keller, L. Klinger, published by American National Red Cross
This work is licensed under the Creative Commons License.

Previous article Volume 36 (2020): Issue 4 (December 2020)Next article